Scholarlink

<p>Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Influenza neuraminidase as adjuvanted protein or mRNA vaccine protects mice against influenza A and B virus challenge

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • João Paulo Portela Catani,
  • Anouk Smet,
  • Tine Ysenbaert,
  • Laura Amelinck,
  • Raul C. Gomila,
  • Xavier Saelens,
  • Thorsten U. Vogel

摘要

Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.